SUANFARMA AQUIRES CIPAN

Suanfarma acquires CIPAN, a public listed Portuguese company

Suanfarma has successfully completed the acquisition of CIPAN (Companhia Industrial Productora de Antibioticos), a prestigious internationally recognized company, pioneer in the production of Antibiotics. Cipan was founded in 1963 in Castanheira do Ribatejo, 30 km north of Lisbon. Their factory is FDA approved, has 800.000 liters of reaction capacity both in fermentation and chemical synthesis processes. Cipan is listed in the EASYNEXT index in Portugal, so Suanfarma has carried out an IPO for a 15% of the free float share capital of the company.

With this acquisition, the third one so far in 2016 following Distribuidora Disandalo in Colombia and Idifarma in Pamplona, Spain, Suanfarma has carried out the industrial investments planned for 2016 after the entry of its latest shareholder, ProA Capital, which acquired a stake in the company in October 2015. CIPAN completes the production of active pharmaceutical ingredients both biotechnological processes (fermentation) and chemical synthesis.

This way, the Spanish company, has significantly reinforced its industrial and development capabilities, and will be able to start the production of its own products on the antidiabetic and probiotic fields, which are currently in R&D phase.

Read More
Minocycline

Increasing Minocycline production

Cipan is increasing its production of Minocycline HCl in 2017. With a production capacity of 30 Ton/year, Cipan has produced small amounts of this product in the last few years. In 2017, we are significantly increasing the output of Minocycline HCl.

Minocycline is a tetracycline antibiotic and therefore fights bacterial infections  in the human body. Minocycline is used to treat many different bacterial infections, such as urinary tract infections, respiratory infections, but mainly skin infections.

Read More